Real-world experience of Guselkumab in the elderly population

Introduction

Psoriasis, a chronic inflammatory skin condition affecting 2–3% of the world population,¹ impacts quality of life and has the highest burden in the age groups of 60–64 and 65–69 years.² A few studies have tried to estimate the…